The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim safety analysis of a randomized phase II trial comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with advanced pancreatic cancer
 
Hiroaki Yanagimoto
No Relationships to Disclose
 
Takuji Okusaka
Honoraria - Bayer; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Chugai Pharma; Dainippon Sumitomo Pharma; Lilly; NanoCarrier; Nippon Boehringer Ingelheim; Nobelpharma; Novartis; OncoTherapy Science; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Sceti Medical Labo (Inst); Shizuoka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Hiroshi Ishii
Honoraria - Ajinomoto; Bayer; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Torii Pharmaceutical
 
Junji Furuse
Honoraria - Ajinomoto; Astellas Pharma; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly; Meiji Seika Kaisha; Merck Serono; Mitsubishi Tanabe Pharma; Nippon Kayaku; Ono Pharmaceutical; Sandoz; Sanofi; Shionogi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Eisai; Fujifilm; GlaxoSmithKline; Janssen; Kowa; Kyowa Hakko Kirin; Merck Serono; Otsuka; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Torii Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Shinichi Ohkawa
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; MSD; Pfizer; Taiho Pharmaceutical; Yakult Honsha (I)
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - AstraZeneca; Chugai Pharma; Dainippon Sumitomo Pharma; Lilly; OncoTherapy Science; Taiho Pharmaceutical; Yakult Honsha
 
Akira Fukutomi
Honoraria - Daiichi Sankyo; Lilly; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Yakult Honsha
Research Funding - GlaxoSmithKline (Inst); Merck Serono (Inst); OncoTherapy Science (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); Yakult Honsha (Inst)
 
Tatsuya Ioka
Speakers' Bureau - Chugai Pharma; Eisai; Lilly; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); Bayer (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); Nihon Zouki (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
Other Relationship - Taiho Pharmaceutical
 
Masayuki Sho
No Relationships to Disclose
 
Shoji Nakamori
No Relationships to Disclose
 
Masayuki Kitano
No Relationships to Disclose
 
Kazuya Sugimori
No Relationships to Disclose
 
Hiroyuki Maguchi
No Relationships to Disclose
 
Hiroshi Imaoka
No Relationships to Disclose
 
Hideo Baba
Speakers' Bureau - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma; Takeda; Yakult Honsha
 
Atsushi Shimizu
No Relationships to Disclose
 
Isao Yokota
No Relationships to Disclose
 
Yasuo Ohashi
Stock and Other Ownership Interests - Statwa Co.
Honoraria - Taiho Pharmaceutical
Consulting or Advisory Role - Taiho Pharmaceutical
Research Funding - Astellas Pharma; Takeda
Travel, Accommodations, Expenses - Yakult Honsha
 
Hiroki Yamaue
Research Funding - Taiho Pharmaceutical (Inst)